北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第三临床医学院  > 血液内科  > 期刊论文
学科主题: 临床医学
题名:
Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia
作者: Fu, Lin1,2; Shi, Jinlong3; Hu, Kai1,2; Wang, Jijun1,2; Wang, Weidong3; Ke, Xiaoyan1,2
关键词: MAPKBP1 ; prognostic biomarker ; CN-AML
刊名: ONCOTARGET
发表日期: 2015-04-10
卷: 6, 期:10, 页:8144-8154
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Cell Biology
研究领域[WOS]: Oncology ; Cell Biology
关键词[WOS]: NF-KAPPA-B ; MICRORNA-EXPRESSION SIGNATURES ; OLDER PATIENTS ; DISTINCT GENE ; MUTATIONS ; CANCER ; PROFILES ; SUBTYPES ; IMPACT ; CELLS
英文摘要:

Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is a key transcription factor in the NF-kappa B signalling pathway. In this study, associations between MAPKBP1 expression and molecular and clinical characteristics were evaluated by several microarray datasets. We found that MAPKBP1 was over-expressed in cytogenetically normal AML (CN-AML) patients compared to normal bone marrow. High MAPKBP1 expression (MAPKBP1(high)) was associated with significantly shorter event-free survival (EFS; P = 0.0004) and overall survival (OS; P = 0.0006) than low MAPKBP1 expression (MAPKBP1(low)) in a cohort of 157 CN-AML patients. In multivariable analyses, MAPKBP1(high) remained associated with shorter EFS (P = 0.003) and OS (P = 0.01). Validation in an independent cohort of 162 CN-AML patients further confirmed the prognostic value of MAPKBP1 (OS, P = 0.00172). Gene-expression profiling revealed that some important oncogenes, including MYCN, MYB, CDK6 and CCND2, etc, were up-regulated, while cell signalling pathways leading to apoptosis, antigen processing, and natural killer cell-mediated cytotoxicity were down-regulated in MAPKBP1(high) patients with CN-AML. MicroRNA expression profiling revealed that some oncogenic microRNAs including miR-155 and miR-126 were up-regulated, whilst anti-oncogenic microRNAs including miR-148a and miR-193a were down-regulated in MAPKBP1(high) patients with CN-AML, which may underlie the pathological processes in this malignancy. Taken together, these findings suggest MAPKBP1(high) is a novel, unfavourably prognostic biomarker for CN-AML risk-stratification.

语种: 英语
所属项目编号: 81172245 ; 61372047 ; 2013BAI03B04
项目资助者: National Natural Science Foundation of China ; National High-tech R&amp ; D Program of China
WOS记录号: WOS:000354885300057
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51313
Appears in Collections:北京大学第三临床医学院_血液内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 3, Dept Hematol, Beijing 100871, Peoples R China
2.Peking Univ, Hosp 3, Lymphoma Res Ctr, Beijing 100871, Peoples R China
3.Chinese Peoples Liberat Army Gen Hosp, Med Engn Support Ctr, Beijing 100853, Peoples R China

Recommended Citation:
Fu, Lin,Shi, Jinlong,Hu, Kai,et al. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia[J]. ONCOTARGET,2015,6(10):8144-8154.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fu, Lin]'s Articles
[Shi, Jinlong]'s Articles
[Hu, Kai]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fu, Lin]‘s Articles
[Shi, Jinlong]‘s Articles
[Hu, Kai]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace